About: Evaluation of the Reported Rates of Severe Hypersensitivity Reactions Associated with Ferric Carboxymaltose and Iron (III) Isomaltoside 1000 in Europe Based on Data from EudraVigilance and VigiBase™ between 2014 and 2017

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Evaluation of the Reported Rates of Severe Hypersensitivity Reactions Associated with Ferric Carboxymaltose and Iron (III) Isomaltoside 1000 in Europe Based on Data from EudraVigilance and VigiBase™ between 2014 and 2017 Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 01 March 2019

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) im März 2019 veröffentlichter wissenschaftlicher Artikel (de) artículu científicu espublizáu en marzu de 2019 (ast) scientific article published on 01 March 2019 (en) наукова стаття, опублікована 1 березня 2019 (uk)
publication date	wds:Q90393732-C314386D-ACA8-41D7-87FA-B8014536F9B6
publication date	2019-03-01 00:00:00Z (xsd:dateTime)
cites work	wds:Q90393732-07A38DE3-B798-4A65-B8CB-85E0ABABCACA wds:Q90393732-0BE54877-0343-461B-B930-2481385DB9CE wds:Q90393732-0CCBD348-B771-46EC-AC7B-AEB6E4161471 wds:Q90393732-11EB873B-5122-435C-A41B-F57CE74ED1DA wds:Q90393732-18D22912-BD2D-43E9-A571-3B79ACB523B9 wds:Q90393732-2AA0B41C-7E97-40CA-81A4-86D5B9A6D6DC wds:Q90393732-2CDE2BE8-EE06-47D8-9456-31192005583F wds:Q90393732-54170F9A-9290-447F-9318-FDF92A1A8894 wds:Q90393732-56D8EF73-617A-432E-A6C0-EC30240BEE94 wds:Q90393732-674BA9DE-AE15-4999-B3EC-A8180C78A5EA wds:Q90393732-6F74BF96-B231-455E-ACDB-AC672F458DCF wds:Q90393732-78ED1664-B682-45D3-A976-F5BC8CEF3466 wds:Q90393732-7E1C680F-7A67-4D7E-B1AA-D31F3F7B552C wds:Q90393732-7FC21CDA-018C-4AF2-B24C-68FEC584047B wds:Q90393732-81B9A47B-9DDC-4A09-8DEF-C052DDBD6202 wds:Q90393732-8A59FA91-E71A-48F1-A7D5-A52B7A4E0531 wds:Q90393732-9A00F937-D481-4CC3-BE71-85B8973DA6F3 wds:Q90393732-A6793B6E-0FA1-40CD-B30E-FFD9E1D4BB94 wds:Q90393732-AFBA49B6-21E3-479E-B82B-96136876C128 wds:Q90393732-B654ED89-7292-4D07-A4CC-F96D0CB038E7 wds:Q90393732-BECB8CF8-4712-49B8-A696-CBBEB4D76AC7 wds:Q90393732-C0F7E127-40E1-48AD-925C-4E63229A9B8F wds:Q90393732-CAF67E5A-2768-4695-9B58-9FD8EBB77B6B wds:Q90393732-E0CA979B-D4B2-4080-B9E7-B0E0D50E997D wds:Q90393732-E151DB5E-EE66-4990-9E05-1553322C0476 wds:Q90393732-E31FD844-EE6D-4645-B44B-6BB5A92095CC wds:Q90393732-E8786D57-7A23-4DAD-97A6-A4D75B80BFD6 wds:Q90393732-ED048CD1-259B-407C-AA69-436154F891AE wds:Q90393732-F2A1109E-766E-4C83-B75A-DD63C50A8AE5 wds:Q90393732-FD89E07E-7987-41F7-B915-B5B5A8AABFB5
cites work	Prevalence of anemia in chronic kidney disease in the United States Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015 A comparative study of the physicochemical properties of iron isomaltoside 1000 (Monofer), a new intravenous iron preparation and its clinical implications Structure, chemistry, and pharmacokinetics of intravenous iron agents Hypersensitivity reactions and deaths associated with intravenous iron preparations A randomized, controlled trial comparing IV iron sucrose to oral iron in anemic patients with nondialysis-dependent CKD Revised nomenclature for allergy for global use: Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003. Under-reporting of adverse drug reactions : a systematic review Direct Comparison of the Safety and Efficacy of Ferric Carboxymaltose versus Iron Dextran in Patients with Iron Deficiency Anemia The new generation of intravenous iron: chemistry, pharmacology, and toxicology of ferric carboxymaltose FERGIcor, a randomized controlled trial on ferric carboxymaltose for iron deficiency anemia in inflammatory bowel disease. Ferumoxytol versus placebo in iron deficiency anemia: efficacy, safety, and quality of life in patients with gastrointestinal disorders The complex interplay of iron metabolism, reactive oxygen species, and reactive nitrogen species: insights into the potential of various iron therapies to induce oxidative and nitrosative stress. Dextran hypersensitivity Importance of iron supply for erythropoietin therapy Diagnosis of Iron-Deficiency Anemia in Chronic Kidney Disease The case-population study design: an analysis of its application in pharmacovigilance Intravenous iron: from anathema to standard of care Physico-chemical properties of the new generation IV iron preparations ferumoxytol, iron isomaltoside 1000 and ferric carboxymaltose Drug-specific hypophosphatemia and hypersensitivity reactions following different intravenous iron infusions. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Systematic review with network meta-analysis: comparative efficacy and tolerability of different intravenous iron formulations for the treatment of iron deficiency anaemia in patients with inflammatory bowel disease. Essential but toxic: controlling the flux of iron in the body. Modern iron replacement therapy: clinical and pathophysiological insights. Comparative Risk of Anaphylactic Reactions Associated With Intravenous Iron Products. The available intravenous iron formulations: History, efficacy, and toxicology Intravenous infusion of total dose iron is superior to oral iron in treatment of anemia in peritoneal dialysis patients: a single center comparative study Exposure to inhibitors of the renin-angiotensin system is a major independent risk factor for acute renal failure induced by sucrose-containing intravenous immunoglobulins: a case-control study Differences in spontaneously reported hypersensitivity and serious adverse events for intravenous iron preparations: comparison of Europe and North America Comparison of hypersensitivity reactions of intravenous iron: iron isomaltoside-1000 (Monofer ) versus ferric carboxy-maltose (Ferinject ). A single center, cohort study
author name string	wds:Q90393732-2A1F9526-9A81-4FB7-BFFA-465045CCE4CA wds:Q90393732-8596DC0C-BA5D-4814-987F-B879DB8493BE wds:Q90393732-CACE2FA9-37F8-4B7A-9BFC-5DDF58D836EF wds:Q90393732-CB8BB05B-AED8-4968-A7CC-5A86C13B003A wds:Q90393732-F541C6BE-1C7C-4B67-AF71-14465A040304
author name string	Massoud Toussi Lennart Nathell Derya Bocuk Stefan Wohlfeil Annegret Gohlke
rdfs:label	Evaluation of the Reported Rates of Severe Hypersensitivity Reactions Associated with Ferric Carboxymaltose and Iron (III) Isomaltoside 1000 in Europe Based on Data from EudraVigilance and VigiBase™ between 2014 and 2017 (en) Evaluation of the Reported Rates of Severe Hypersensitivity Reactions Associated with Ferric Carboxymaltose and Iron (III) Isomaltoside 1000 in Europe Based on Data from EudraVigilance and VigiBase™ between 2014 and 2017 (nl)
skos:prefLabel	Evaluation of the Reported Rates of Severe Hypersensitivity Reactions Associated with Ferric Carboxymaltose and Iron (III) Isomaltoside 1000 in Europe Based on Data from EudraVigilance and VigiBase™ between 2014 and 2017 (en) Evaluation of the Reported Rates of Severe Hypersensitivity Reactions Associated with Ferric Carboxymaltose and Iron (III) Isomaltoside 1000 in Europe Based on Data from EudraVigilance and VigiBase™ between 2014 and 2017 (nl)
name	Evaluation of the Reported Rates of Severe Hypersensitivity Reactions Associated with Ferric Carboxymaltose and Iron (III) Isomaltoside 1000 in Europe Based on Data from EudraVigilance and VigiBase™ between 2014 and 2017 (en) Evaluation of the Reported Rates of Severe Hypersensitivity Reactions Associated with Ferric Carboxymaltose and Iron (III) Isomaltoside 1000 in Europe Based on Data from EudraVigilance and VigiBase™ between 2014 and 2017 (nl)
author	wds:Q90393732-95603CD8-E2EC-4B86-B2B4-60CF260ECF06
author	Birgit Ehlken
title	wds:Q90393732-D6A6F450-607F-4D3E-9A3C-968EC0FB4B3B
title	Evaluation of the Reported Rates of Severe Hypersensitivity Reactions Associated with Ferric Carboxymaltose and Iron (III) Isomaltoside 1000 in Europe Based on Data from EudraVigilance and VigiBase™ between 2014 and 2017 (en)
page(s)	wds:Q90393732-671741D1-51DF-4906-8412-6E8276716052
page(s)	463-471
instance of	wds:Q90393732-0723855F-64DB-4DF3-9FD9-0A87D0792E2C
instance of	scholarly article
PubMed ID	wds:Q90393732-B8A9A9EF-1125-462C-9BDA-ACA44970899F
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/30535629
PubMed ID	30535629
published in	wds:Q90393732-24E5C9AF-15F8-43FC-BB99-CECA05B8C5FD
published in	Drug Safety
issue	wds:Q90393732-3F13E1CF-3558-4B1A-87D3-C8E15BD3A9DF
volume	wds:Q90393732-D5A4215D-38EF-4273-BA75-8694EAAE5113
issue	3

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 190 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software